# Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

> **NCT04655976** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 758 (actual)

## Conditions studied

- Lung Cancer, Non-Small Cell

## Interventions

- **BIOLOGICAL:** Cobolimab
- **BIOLOGICAL:** Dostarlimab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04655976
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-08
- **Primary completion:** 2025-06-05
- **Final completion:** 2027-03-30
- **Target enrollment:** 758 (ACTUAL)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04655976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04655976, "Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04655976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*